Subtype
Brain Neoplasm
CI-CAN-00002030Explore in graph →
Non-malignant511 active trials34 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002030Explore in graph →
Clinical trials
2,117 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05685004 | Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 / Phase 3 | 120 | TVAX BiomedicalINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07492316 | RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)(PNOC020 rMB) | active not recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT03994796 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | active not recruiting | Phase 2 | 50 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02015117 | Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases | active not recruiting | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02389309 | Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors | active not recruiting | Phase 1 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04837547 | PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy(PEACH) | active not recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT02792582 | A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection | active not recruiting | Phase 2 | 160 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03197506 | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | active not recruiting | Phase 2 | 52 | Mayo ClinicOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT03698994 | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 21, 2026 | clinicaltrials |
| NCT05050929 | RAPid SimPLE Targeted Radiation Treatment for Brain Metastases(RAPPLE) | active not recruiting | Phase 2 | 100 | British Columbia Cancer AgencyOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03158064 | Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03508752 | Neurocognitive Decline in Patients With Brain Metastases | active not recruiting | Phase 1 / Phase 2 | 80 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04114981 | Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery | active not recruiting | Phase 3 | 242 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT01592968 | Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases | active not recruiting | Phase 3 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02442297 | T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors(iCAR) | active not recruiting | Phase 1 | 10 | Baylor College of MedicineOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05438212 | Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | active not recruiting | Phase 3 | 237 | NRG OncologyOTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | active not recruiting | Phase 1 | 148 | PfizerINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT04181684 | LITT Followed by Hypofractionated RT for Recurrent Gliomas(GCCC 19140) | active not recruiting | N/A | 39 | University of Maryland, BaltimoreOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT02693990 | A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas | active not recruiting | N/A | 21 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT00268385 | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | active not recruiting | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT01419067 | A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection | active not recruiting | Phase 2 | 112 | St. Jude Children's Research HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07091396 | Home Transcranial Direct Current Stimulation (tDCS) to Enhance Functional Recovery | active not recruiting | N/A | 55 | Mayo ClinicOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06632236 | 5G-EMERALD: Amivantamab in Malignant Brain Tumours(5G-EMERALD) | active not recruiting | Phase 1 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06894979 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 54 | Children's Oncology GroupNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03652545 | Multi-antigen T Cell Infusion Against Neuro-oncologic Disease(REMIND) | active not recruiting | Phase 1 | 33 | Catherine BollardOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04940507 | BRAINFUL (BRAIN Tumor Focused Ultrasound-enabled Liquid Biopsy) Trial(BRAINFUL) | active not recruiting | N/A | 50 | University Health Network, TorontoOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06777433 | Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases(RAD101) | active not recruiting | Phase 2 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT00950001 | Stereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases | active not recruiting | Phase 3 | 132 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03606161 | Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Brain Tumors | active not recruiting | N/A | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03741673 | Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | active not recruiting | Phase 3 | 180 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03281889 | Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation | active not recruiting | N/A | 20 | Massachusetts General HospitalOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | active not recruiting | Phase 1 / Phase 2 | 10 | Julie KrystalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03604302 | Evaluation of Preoperative Functional Magnetic Resonance Imaging (fMRI) in Patients With Brain Tumors | active not recruiting | N/A | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT07259304 | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | active not recruiting | — | 118 | University of Southern CaliforniaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03598244 | Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | active not recruiting | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Jul 30, 2026 | clinicaltrials |
| NCT04337177 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | active not recruiting | Phase 1 | 20 | Valent Technologies, LLCINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05047913 | Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR | active not recruiting | Early Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02191488 | ALA-induced PpIX Fluorescence During Brain Tumor Resection | active not recruiting | Phase 1 | 540 | David W. RobertsOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02691923 | Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker | active not recruiting | Phase 2 | 30 | David W. RobertsOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04743661 | 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma | active not recruiting | Phase 2 | 62 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT02288962 | Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas | active not recruiting | Phase 3 | 60 | St. Olavs HospitalOTHER | 2 | Jul 21, 2026 | clinicaltrials |
| NCT02886585 | Pembrolizumab In Central Nervous System Metastases | active not recruiting | Phase 2 | 101 | Massachusetts General HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02359565 | Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma | active not recruiting | Phase 1 | 71 | National Cancer Institute (NCI)NIH | 2 | Jul 20, 2026 | clinicaltrials |
| NCT03423628 | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | active not recruiting | Phase 1 | 159 | AstraZenecaINDUSTRY | 3 | Jul 17, 2026 | clinicaltrials |
| NCT02724579 | Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma | active not recruiting | Phase 2 | 45 | Children's Oncology GroupNETWORK | 5 | Jul 16, 2026 | clinicaltrials |
| NCT04062305 | nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex | active not recruiting | N/A | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials